Relay Therapeutics, a Cambridge, Mass.-based company working at the intersection of computation and biotechnology, completed a $400m Series C financing.
The round was led by the SoftBank Vision Fund with participation from new investors Foresite Capital, Perceptive Advisors and Tavistock Group and existing investors GV, Casdin Capital, BVF Partners, EcoR1 Capital, Alexandria Venture Investments, and an affiliate of D.E. Shaw Research.
The company intends to use the funds to accelerate expansion of its discovery efforts, advance existing programs into the clinic and bolster its broad platform and diverse team.
Launched in 2016 and led by Sanjiv Patel, M.D., President and Chief Executive Officer, Relay Therapeutics combines computational skills with experimental approaches across the fields of structural biology, biophysics, chemistry and biology. The integration of these disparate disciplines, tools and cultures enables the company to design therapies against validated but previously intractable targets. Its initial discovery programs in cancer have led to the development of highly selective inhibitors of disease-causing proteins in genomically defined patient populations.
Prior to the Series C, Relay Therapeutics had raised $120m.